Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma.

Kato J, O'Donnell RT, Abuhay M, Tuscano JM.

Oncoimmunology. 2012 Dec 1;1(9):1469-1475.

PMID:
23264893
[PubMed]
Free PMC Article
2.

Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.

Kato J, Satake N, O'Donnell RT, Abuhay M, Lewis C, Tuscano JM.

Leuk Res. 2013 Jan;37(1):83-8. doi: 10.1016/j.leukres.2012.09.010. Epub 2012 Oct 4.

PMID:
23040543
[PubMed - indexed for MEDLINE]
3.

Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.

O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM.

Cancer Immunol Immunother. 2009 Oct;58(10):1715-22. doi: 10.1007/s00262-009-0688-5. Epub 2009 Mar 18.

PMID:
19294384
[PubMed - indexed for MEDLINE]
4.

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.

Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, Lau J, Yu SF, Du C, Fuh F, Tan C, Wu Y, Liang WC, Prabhu S, Stephan JP, Hongo JA, Dere RC, Deng R, Cullen M, de Tute R, Bennett F, Rawstron A, Jack A, Ebens A.

Leukemia. 2010 Sep;24(9):1566-73. doi: 10.1038/leu.2010.141. Epub 2010 Jul 1.

PMID:
20596033
[PubMed - indexed for MEDLINE]
5.

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.

Martin SM, Churchill E, McKnight H, Mahaffey CM, Ma Y, O'Donnell RT, Tuscano JM.

J Hematol Oncol. 2011 Dec 1;4:49. doi: 10.1186/1756-8722-4-49.

PMID:
22128838
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.

Kong Y, Barisone GA, Abuhay M, O'Donnell RT, Buksh Z, Yousefian F, Tuscano JM.

Leuk Res. 2014 Nov;38(11):1320-6. doi: 10.1016/j.leukres.2014.08.014. Epub 2014 Aug 30.

PMID:
25241275
[PubMed - in process]
7.

Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.

Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT.

Clin Cancer Res. 2010 May 15;16(10):2760-8. doi: 10.1158/1078-0432.CCR-09-3199. Epub 2010 May 11.

PMID:
20460479
[PubMed - indexed for MEDLINE]
Free Article
8.

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.

O'Donnell RT, Ma Y, McKnight HC, Pearson D, Tuscano JM.

Cancer Immunol Immunother. 2009 Dec;58(12):2051-8. doi: 10.1007/s00262-009-0713-8. Epub 2009 May 13.

PMID:
19437017
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL.

Blood. 2003 May 1;101(9):3641-7. Epub 2003 Jan 2.

PMID:
12511412
[PubMed - indexed for MEDLINE]
Free Article
10.

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.

Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM.

Clin Cancer Res. 2004 Apr 15;10(8):2868-78.

PMID:
15102696
[PubMed - indexed for MEDLINE]
Free Article
11.

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Vaklavas C, Forero-Torres A.

Ther Adv Hematol. 2012 Aug;3(4):209-25. doi: 10.1177/2040620712443076.

PMID:
23606932
[PubMed]
Free PMC Article
12.

Brentuximab vedotin in Hodgkin's lymphoma.

Pro B, Perini GF.

Expert Opin Biol Ther. 2012 Oct;12(10):1415-21. doi: 10.1517/14712598.2012.718328. Epub 2012 Aug 31. Review.

PMID:
22937794
[PubMed - indexed for MEDLINE]
13.

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.

DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK.

Cancer Immunol Immunother. 2005 Jan;54(1):11-24.

PMID:
15693135
[PubMed - indexed for MEDLINE]
14.

Antibody-drug conjugate technology development for hematologic disorders.

Bander NH, Czuczman MS, Younes A.

Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 10):1-16.

PMID:
23072775
[PubMed - indexed for MEDLINE]
15.

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, Frantz G, Fuji RN, Gray A, Harden K, Ingle GS, Kljavin NM, Koeppen H, Nelson C, Prabhu S, Raab H, Ross S, Slaga DS, Stephan JP, Scales SJ, Spencer SD, Vandlen R, Wranik B, Yu SF, Zheng B, Ebens A.

Cancer Res. 2009 Mar 15;69(6):2358-64. doi: 10.1158/0008-5472.CAN-08-2250. Epub 2009 Mar 3. Erratum in: Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added].

PMID:
19258515
[PubMed - indexed for MEDLINE]
Free Article
16.

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).

O'Donnell RT, Martin SM, Ma Y, Zamboni WC, Tuscano JM.

Invest New Drugs. 2010 Jun;28(3):260-7. doi: 10.1007/s10637-009-9243-7. Epub 2009 Mar 24.

PMID:
19306119
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Brentuximab Vedotin in CD30+ Lymphomas.

Perini GF, Pro B.

Biol Ther. 2013;3:15-23. Epub 2013 Mar 1. Review.

PMID:
24392301
[PubMed]
Free PMC Article
18.

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG.

Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18.

PMID:
23598530
[PubMed - indexed for MEDLINE]
Free Article
19.

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

Chen X, Soma LA, Fromm JR.

Onco Targets Ther. 2013 Dec 19;7:45-56. doi: 10.2147/OTT.S39107. Review.

PMID:
24379682
[PubMed]
Free PMC Article
20.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk